

This PDF is a selection from a published volume from the National Bureau of Economic Research

Volume Title: Economic Dimensions of Personalized and Precision Medicine

Volume Authors/Editors: Ernst R. Berndt, Dana P. Goldman, and John W. Rowe, editor

Volume Publisher: University of Chicago Press

Volume ISBNs: 978-0-226-61106-8 (cloth); 978-0-226-61123-5 (electronic)

Volume URL: <http://www.nber.org/books/bern-13>

Conference Date: September 13–14, 2017

Publication Date: April 2019

Chapter Title: Front matter, acknowledgments

Chapter Author(s):


Chapter URL: <http://www.nber.org/chapters/c14531>

Chapter pages in book: (p. i – x)

Economic Dimensions of Personalized and Precision Medicine



**National Bureau of
Economic Research
Conference Report**



Economic Dimensions of Personalized and Precision Medicine

Edited by

**Ernst R. Berndt, Dana P. Goldman,
and John W. Rowe**

The University of Chicago Press

Chicago and London

The University of Chicago Press, Chicago 60637
The University of Chicago Press, Ltd., London
© 2019 by the National Bureau of Economic Research
All rights reserved. No part of this book may be used or reproduced
in any manner whatsoever without written permission, except in the
case of brief quotations in critical articles and reviews. For more
information, contact the University of Chicago Press, 1427 E. 60th St.,
Chicago, IL 60637.
Published 2019
Printed in the United States of America

28 27 26 25 24 23 22 21 20 19 1 2 3 4 5

ISBN-13: 978-0-226-61106-8 (cloth)
ISBN-13: 978-0-226-61123-5 (e-book)
DOI: <https://doi.org/10.7208/chicago/9780226611235.001.0001>

Library of Congress Cataloging-in-Publication Data

Names: Berndt, Ernst R., editor. | Goldman, Dana P. (Dana Paul),
1966– editor. | Rowe, John (Professor of Health Policy), editor.
Title: Economic dimensions of personalized and precision medicine /
Ernst R. Berndt, Dana Goldman, and John Rowe, editors.
Other titles: National Bureau of Economic Research conference report.
Description: Chicago ; London : The University of Chicago Press,
2019. |
Series: National Bureau of Economic Research conference report |
Includes bibliographical references and index.
Identifiers: LCCN 2018037553 | ISBN 9780226611068 (cloth : alk.
paper) |
ISBN 9780226611235 (ebook)
Subjects: LCSH: Pharmacogenetics. | Personalized medicine—
Economic aspects—United States.
Classification: LCC RM301.3.G45 E265 2019 | DDC 615.7—dc23
LC record available at <https://lcn.loc.gov/2018037553>

© This paper meets the requirements of ANSI/NISO Z39.48-1992
(Permanence of Paper).

National Bureau of Economic Research

Officers

Karen N. Horn, *chair*

John Lipsky, *vice chair*

James M. Poterba, *president and chief executive officer*

Robert Mednick, *treasurer*

Kelly Horak, *controller and assistant corporate secretary*

Alterra Milone, *corporate secretary*

Denis Healy, *assistant corporate secretary*

Directors at Large

Peter C. Aldrich

Elizabeth E. Bailey

John H. Biggs

John S. Clarkeson

Kathleen B. Cooper

Charles H. Dallara

George C. Eads

Jessica P. Einhorn

Mohamed El-Erian

Diana Farrell

Jacob A. Frenkel

Robert S. Hamada

Peter Blair Henry

Karen N. Horn

Lisa Jordan

John Lipsky

Laurence H. Meyer

Karen Mills

Michael H. Moskow

Alicia H. Munnell

Robert T. Parry

James M. Poterba

John S. Reed

Marina v. N. Whitman

Martin B. Zimmerman

Directors by University Appointment

Timothy Bresnahan, *Stanford*

Pierre-André Chiappori, *Columbia*

Alan V. Deardorff, *Michigan*

Edward Foster, *Minnesota*

John P. Gould, *Chicago*

Mark Grinblatt, *California, Los Angeles*

Bruce Hansen, *Wisconsin–Madison*

Benjamin Hermalin, *California, Berkeley*

Samuel Kortum, *Yale*

George Mailath, *Pennsylvania*

Marjorie B. McElroy, *Duke*

Joel Mokyr, *Northwestern*

Cecilia Rouse, *Princeton*

Richard L. Schmalensee, *Massachusetts Institute of Technology*

Ingo Walter, *New York*

David B. Yoffie, *Harvard*

Directors by Appointment of Other Organizations

Jean-Paul Chavas, *Agricultural and Applied Economics Association*

Martin J. Gruber, *American Finance Association*

Philip Hoffman, *Economic History Association*

Arthur Kennickell, *American Statistical Association*

Jack Kleinhenz, *National Association for Business Economics*

Robert Mednick, *American Institute of Certified Public Accountants*

Peter L. Rousseau, *American Economic Association*

Gregor W. Smith, *Canadian Economics Association*

William Spriggs, *American Federation of Labor and Congress of Industrial Organizations*

Bart van Ark, *The Conference Board*

Directors Emeriti

George Akerlof

Jagdish Bhagwati

Don R. Conlan

Ray C. Fair

Franklin Fisher

Saul H. Hymans

Rudolph A. Oswald

Andrew Postlewaite

John J. Siegfried

Craig Swan

**Relation of the Directors to the
Work and Publications of the
National Bureau of Economic Research**

1. The object of the NBER is to ascertain and present to the economics profession, and to the public more generally, important economic facts and their interpretation in a scientific manner without policy recommendations. The Board of Directors is charged with the responsibility of ensuring that the work of the NBER is carried on in strict conformity with this object.

2. The President shall establish an internal review process to ensure that book manuscripts proposed for publication DO NOT contain policy recommendations. This shall apply both to the proceedings of conferences and to manuscripts by a single author or by one or more co-authors but shall not apply to authors of comments at NBER conferences who are not NBER affiliates.

3. No book manuscript reporting research shall be published by the NBER until the President has sent to each member of the Board a notice that a manuscript is recommended for publication and that in the President's opinion it is suitable for publication in accordance with the above principles of the NBER. Such notification will include a table of contents and an abstract or summary of the manuscript's content, a list of contributors if applicable, and a response form for use by Directors who desire a copy of the manuscript for review. Each manuscript shall contain a summary drawing attention to the nature and treatment of the problem studied and the main conclusions reached.

4. No volume shall be published until forty-five days have elapsed from the above notification of intention to publish it. During this period a copy shall be sent to any Director requesting it, and if any Director objects to publication on the grounds that the manuscript contains policy recommendations, the objection will be presented to the author(s) or editor(s). In case of dispute, all members of the Board shall be notified, and the President shall appoint an ad hoc committee of the Board to decide the matter; thirty days additional shall be granted for this purpose.

5. The President shall present annually to the Board a report describing the internal manuscript review process, any objections made by Directors before publication or by anyone after publication, any disputes about such matters, and how they were handled.

6. Publications of the NBER issued for informational purposes concerning the work of the Bureau, or issued to inform the public of the activities at the Bureau, including but not limited to the NBER Digest and Reporter, shall be consistent with the object stated in paragraph 1. They shall contain a specific disclaimer noting that they have not passed through the review procedures required in this resolution. The Executive Committee of the Board is charged with the review of all such publications from time to time.

7. NBER working papers and manuscripts distributed on the Bureau's web site are not deemed to be publications for the purpose of this resolution, but they shall be consistent with the object stated in paragraph 1. Working papers shall contain a specific disclaimer noting that they have not passed through the review procedures required in this resolution. The NBER's web site shall contain a similar disclaimer. The President shall establish an internal review process to ensure that the working papers and the web site do not contain policy recommendations, and shall report annually to the Board on this process and any concerns raised in connection with it.

8. Unless otherwise determined by the Board or exempted by the terms of paragraphs 6 and 7, a copy of this resolution shall be printed in each NBER publication as described in paragraph 2 above.

Contents

	Acknowledgment	ix
	Introduction	1
	Ernst R. Berndt, Dana P. Goldman, and John W. Rowe	
1.	The Economic Value and Pricing of Personalized Medicine	9
	Tomas J. Philipson	
2.	Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS	21
	Manuel Hermosilla and Jorge Lemus	
3.	The Value of Pharmacogenomic Information	53
	John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson	
4.	The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory	87
	Ernst R. Berndt and Mark R. Trusheim	
5.	Characterizing the Drug Development Pipeline for Precision Medicines	115
	Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern	
6.	Cost Sharing in Insurance Coverage for Precision Medicine	159
	Mark V. Pauly	

7.	Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments Kristopher J. Hult	185
8.	Physicians' Financial Incentives to Personalize Medicine David H. Howard, Jason Hockenberry, and Guy David	217
9.	Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang	237
10.	The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright	273
11.	Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies Philippe Gorry and Diego Useche	305
	Contributors	335
	Author Index	339
	Subject Index	345

Acknowledgment

We wish to extend our gratitude to the organizations that helped make this book possible. The initial concept for this work grew out of a workshop on the clinical and social dimensions of precision medicine that was organized by the Columbia University Precision Medicine program. This book was developed as a part of the Economics of Precision and Personalized Medicine conference, hosted by the National Bureau of Economic Research (NBER) and organized by the editors of this volume.

The conference convened leading researchers in health economics, medicine, and health policy to explore economic issues related to the increasing capacity to develop PPM. The event took the form of two sessions, both picturesque in setting: a preconference at the Columbia University Italian Academy in New York City in September 2016, followed by a two-day research workshop at Shutters on the Beach Hotel in Santa Monica, CA, in September 2017. We would like to acknowledge and thank the attendees for their participation and insight, the NBER conference staff for their competent management of the logistics, and the organizations that sponsored the event, including the University of Southern California Leonard D. Schaeffer Center for Health Policy & Economics, the Columbia University Precision Medicine program, and NBER.

